Live Earnings Conference Call: Geron will host a live Q2 2025 earnings call on August 6, 2025 at 8:00AM ET. Follow this link to get details and listen to Geron's Q2 2025 earnings call when it goes live. Get details. Geron (GERN) Competitors $1.20 -0.01 (-0.83%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$1.22 +0.02 (+1.67%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GERN vs. ALKS, LGND, FOLD, BCRX, CLDX, DVAX, MNKD, INVA, NVAX, and OPKShould you be buying Geron stock or one of its competitors? The main competitors of Geron include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), MannKind (MNKD), Innoviva (INVA), Novavax (NVAX), and OPKO Health (OPK). These companies are all part of the "biotechnology" industry. Geron vs. Its Competitors Alkermes Ligand Pharmaceuticals Amicus Therapeutics BioCryst Pharmaceuticals Celldex Therapeutics Dynavax Technologies MannKind Innoviva Novavax OPKO Health Alkermes (NASDAQ:ALKS) and Geron (NASDAQ:GERN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk. Which has more volatility and risk, ALKS or GERN? Alkermes has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, Geron has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Does the media favor ALKS or GERN? In the previous week, Alkermes had 25 more articles in the media than Geron. MarketBeat recorded 29 mentions for Alkermes and 4 mentions for Geron. Alkermes' average media sentiment score of 0.91 beat Geron's score of -0.26 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 13 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer ALKS or GERN? Alkermes currently has a consensus target price of $41.08, suggesting a potential upside of 54.45%. Geron has a consensus target price of $4.61, suggesting a potential upside of 284.26%. Given Geron's higher probable upside, analysts clearly believe Geron is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83Geron 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.60 Is ALKS or GERN more profitable? Alkermes has a net margin of 23.15% compared to Geron's net margin of -119.54%. Alkermes' return on equity of 24.86% beat Geron's return on equity.Company Net Margins Return on Equity Return on Assets Alkermes23.15% 24.86% 17.14% Geron -119.54%-47.86%-26.78% Do insiders & institutionals hold more shares of ALKS or GERN? 95.2% of Alkermes shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 4.4% of Alkermes shares are owned by insiders. Comparatively, 7.4% of Geron shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better valuation and earnings, ALKS or GERN? Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkermes$1.56B2.82$367.07M$2.0812.79Geron$76.99M9.93-$174.57M-$0.21-5.71 SummaryAlkermes beats Geron on 12 of the 16 factors compared between the two stocks. Get Geron News Delivered to You Automatically Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GERN vs. The Competition Export to ExcelMetricGeronMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$770.67M$3.07B$5.59B$9.53BDividend YieldN/A2.41%4.73%4.14%P/E Ratio-5.7117.5328.9123.88Price / Sales9.93313.17448.7998.82Price / CashN/A42.6035.6858.35Price / Book2.617.828.165.60Net Income-$174.57M-$54.52M$3.25B$265.26M7 Day Performance9.09%2.86%1.15%-0.14%1 Month Performance-15.79%17.29%8.25%6.08%1 Year Performance-73.91%13.27%29.18%24.22% Geron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GERNGeron2.933 of 5 stars$1.20-0.8%$4.61+284.3%-73.4%$770.67M$76.99M-5.71229ALKSAlkermes4.7683 of 5 stars$26.49-5.2%$41.08+55.1%-4.5%$4.61B$1.56B12.741,800Analyst RevisionLGNDLigand Pharmaceuticals4.2056 of 5 stars$131.58-2.7%$150.00+14.0%+37.7%$2.61B$167.13M-18.4880Positive NewsUpcoming EarningsFOLDAmicus Therapeutics4.1279 of 5 stars$5.99-2.3%$16.22+170.8%-26.8%$1.89B$528.29M-66.55480High Trading VolumeBCRXBioCryst Pharmaceuticals4.5469 of 5 stars$8.14-1.0%$16.70+105.2%+11.3%$1.72B$450.71M-31.31530Trending NewsEarnings ReportAnalyst ForecastCLDXCelldex Therapeutics1.3288 of 5 stars$21.98-3.6%$50.11+128.0%-32.4%$1.51B$7.02M-8.14150News CoveragePositive NewsDVAXDynavax Technologies4.2072 of 5 stars$10.98-1.7%$24.00+118.6%+10.7%$1.34B$277.25M-21.12350Upcoming EarningsMNKDMannKind3.5406 of 5 stars$3.78-2.3%$9.86+160.8%-23.7%$1.18B$285.50M37.80400INVAInnoviva4.2143 of 5 stars$18.17-1.4%$40.33+122.0%+0.7%$1.16B$358.71M-17.99100Positive NewsNVAXNovavax4.6095 of 5 stars$6.65-2.9%$15.86+138.5%-40.9%$1.11B$682.16M2.511,990OPKOPKO Health4.1426 of 5 stars$1.28-4.5%$2.75+114.8%-3.8%$1.06B$713.10M-18.282,997Earnings Report Related Companies and Tools Related Companies ALKS Competitors LGND Competitors FOLD Competitors BCRX Competitors CLDX Competitors DVAX Competitors MNKD Competitors INVA Competitors NVAX Competitors OPK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GERN) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredStrange twist to Bitcoin’s rallyThe #1 crypto to buy today Better than Bitcoin? (top crypto for less than $1) Over the past 15 years, B...Stansberry Research | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Geron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GERN Stock Alerts